https://www.pharmaceutical-technology.com/data-insights/denileukin-diftitox-citius-pharmaceuticals-epithelial-ovarian-cancer-likelihood-of-approval/
Denileukin diftitox is under clinical development by Citius Pharmaceuticals and currently in Phase II for Epithelial Ovarian Cancer.
epithelial ovarian cancerdenileukin diftitoxpharmaceuticalslikelihood
https://www.scirp.org/journal/paperinformation?paperid=27457
Comparing survival rates of patients with recurrent ovarian cancer who underwent fertility-sparing surgery (FSS) versus radical surgery. Preliminary analysis...
clinical outcomepatientsstageepithelialovarian
https://www.pharmaceutical-technology.com/data-insights/sitravatinib-malate-bristol-myers-squibb-epithelial-ovarian-cancer-likelihood-of-approval/
Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Epithelial Ovarian Cancer.
bristol myers squibbepithelial ovarian cancersitravatinibmalate
https://www.omicsonline.org/proceedings/association-between-mir200c-and-the-survival-of-patients-with-stage-i-epithelial-ovarian-cancer-a-retrospective-study-of-two-independent-tumour-tissue-9242.html
Background: International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer (EOC) has a significantly better prognosis than stage...
associationmirsurvivalpatients